{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:18:06Z","timestamp":1791292686647,"version":"4.1.0"},"reference-count":62,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T00:00:00Z","timestamp":1343174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:p>Ofatumumab is the first human anti\u2010CD20 monoclonal antibody to be approved for patients in the United States and the European Union. Ofatumumab received accelerated approval from the U.S. Food and Drug Administration in October 2009 and was granted a conditional marketing authorization by the European Medicines Agency in April 2010 for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab, based on interim results of a pivotal phase 2 trial. Preliminary positive results for ofatumumab in combination with chemotherapy in patients with CLL are currently being confirmed in larger randomized trials in both the frontline setting and the relapsed\/refractory setting. Ofatumumab has also shown potential in treating B cell non\u2010Hodgkin's lymphoma, such as follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and Waldenstr\u00f6m's macroglobulinemia. Additional trials are ongoing to confirm activity of ofatumumab as monotherapy and in combination with chemotherapy in patients with FL or DLBCL.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2012.06661.x","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T18:17:14Z","timestamp":1343240234000},"page":"43-56","source":"Crossref","is-referenced-by-count":48,"title":["Ofatumumab, the first human anti\u2010CD20 monoclonal antibody for the treatment of B cell hematologic malignancies"],"prefix":"10.1111","volume":"1263","author":[{"given":"Ira V.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,25]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"NCCN.\u201cNCCN Clinical Practice Guidelines in Oncology. NCCN Non\u2010Hodgkin's lymphoma Guidelines Vers 2 \u201d NCCN. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed 22 March 2012."},{"key":"e_1_2_7_3_2","unstructured":"SEER.\u201cStat Fact Sheets: Chronic Lymphocytic Leukemia \u201d Surveillance Epidemiology and End Results. Available at:http:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed 22 March 2012."},{"key":"e_1_2_7_4_2","unstructured":"SEER.\u201cFast Stats: Chronic Lymphocytic Leukemia Prevalence \u201d Surveillance Epidemiology and End Results. Available at:http:\/\/seer.cancer.gov\/faststats\/selections.php?run=runit&output=2&data=5&statistic=9&race=1&sex=1&age=1&series=cancer&cancer=93#Output. Accessed 22 March 2012."},{"key":"e_1_2_7_5_2","unstructured":"SEER.\u201cStat Fact Sheets: Non\u2010Hodgkin Lymphoma \u201d Surveillance Epidemiology and End Results. Available at:http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html#. Accessed 22 March 2012."},{"key":"e_1_2_7_6_2","unstructured":"ACS.\u201cDetailed Guide: \u2018What Is Non\u2010Hodgkin Lymphoma?\u2019 \u201d American Cancer Society. Available at:http:\/\/www.cancer.org\/Cancer\/Non\u2010HodgkinLymphoma\/DetailedGuide\/non\u2010hodgkin\u2010lymphoma\u2010types\u2010of\u2010non\u2010hodgkin\u2010lymphoma. Accessed 22 March 2012."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712590903586239"},{"key":"e_1_2_7_8_2","unstructured":"NCCN.\u201cNCCN Clinical Practice Guidelines in Oncology. NCCN Waldenstrom's macroglobulinemia\/lymphoplasmacytic lymphoma Guidelines Vers 1 \u201d NCCN. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed 22 March 2012."},{"key":"e_1_2_7_9_2","unstructured":"Genentech. \u201cRituxan (rituximab) prescribing information.\u201d Available at:http:\/\/www.gene.com\/gene\/products\/information\/pdf\/rituxan\u2010prescribing.pdf. Accessed 25 February 2012."},{"key":"e_1_2_7_10_2","unstructured":"GlaxoSmithKline. \u201cArzerra (ofatumumab) prescribing information.\u201d Available at:http:\/\/www.gsksource.com\/gskprm\/htdocs\/documents\/ARZERRA.PDF. Accessed 25 February 2012."},{"key":"e_1_2_7_11_2","unstructured":"GlaxoSmithKline. \u201cBexxar (tositumomab and iodine I 131 tositumomab) prescribing information.\u201d Available at:http:\/\/us.gsk.com\/products\/assets\/us_bexxar.pdf. Accessed 4 April 2012."},{"key":"e_1_2_7_12_2","unstructured":"Spectrum Pharmaceuticals Inc. \u201cZevalin (ibritumomab tiuxetan) prescribing information.\u201d Available at:http:\/\/www.zevalin.com\/wp\u2010content\/uploads\/2012\/03\/Zevalin_Package_Insert.pdf. Accessed 4 April 2012."},{"key":"e_1_2_7_13_2","unstructured":"Genzyme. \u201cCampath (alemtuzumab) prescribing information.\u201d Available at:http:\/\/www.campath.com\/pdfs\/2009\u201008\u2010Campath%20US%20PI.pdf. Accessed 25 February 2012."},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.27.9836"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900632"},{"key":"e_1_2_7_18_2","first-page":"51","article-title":"Ofatumumab (Arzerra) for CLL","volume":"52","year":"2010","journal-title":"Med. Lett. Drugs Ther."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.15"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003717746"},{"key":"e_1_2_7_21_2","first-page":"45","article-title":"The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia","volume":"5","author":"Nabhan C.","year":"2011","journal-title":"Clin. Med. Insights"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P780"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.069"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.223"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/11539590-000000000-00000"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/11203850-000000000-00000"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2010.46.7.1497416"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.4.8895"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111781"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187"},{"key":"e_1_2_7_31_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.921.921","article-title":"Final analysis from the international trial of single\u2010agent ofatumumab in patients with fludarabine\u2010refractory chronic lymphocytic leukemia. Presented at the 52nd Annual Meeting of the American Society of Hematology, Orlando","volume":"116","author":"Wierda W.G.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11871"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348656"},{"key":"e_1_2_7_35_2","unstructured":"GlaxoSmithKline.\u201cGSK and Genmab receive accelerated approval for Arzerra\u2122 \u201d news release April 19 2010 October 26 2009. Available at:http:\/\/www.gsk.com\/media\/pressreleases\/2009\/2009_us_pressrelease_10077.htm. Accessed 5 April 2012."},{"key":"e_1_2_7_36_2","unstructured":"GlaxoSmithKline. \u201cGlaxoSmithKline receives conditional marketing authorization in the EU for Arzerra\u00ae(ofatumumab) \u201dnews release April 19 2010. Available at:http:\/\/www.gsk.com\/media\/pressreleases\/2010\/2010_pressrelease_10038.htm. Accessed 5 April 2012."},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-323980"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-378323"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09086.x"},{"key":"e_1_2_7_44_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3955.3955","article-title":"Ofatumumab monotherapy for treatment of patients with relapsed\/progressive diffuse large B\u2010cell lymphoma: results from a multicenter phase II study. Presented at the 52nd Annual Meeting of the American Society of Hematology, Orlando","volume":"116","author":"Coiffier B.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_7_45_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.957.957","article-title":"A phase II study of ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory aggressive B\u2010cell lymphoma prior to autologous stem cell transplantation (ASCT). Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego","volume":"118","author":"Matasar M.J.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_7_47_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3701.3701","article-title":"A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia. Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego","volume":"118","author":"Furman R.R.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08193.x"},{"key":"e_1_2_7_49_2","unstructured":"GlaxoSmithKline. Data on file."},{"key":"e_1_2_7_50_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3433.3433","article-title":"Correlation between serum ofatumumab concentrations, baseline patient characteristics and clinical outcomes in patients with fludarabine\u2010refractory chronic lymphocytic leukemia (CLL) treated with single\u2010agent ofatumumab. Presented at the 51st Annual Meeting of the American Society of Hematology, New Orleans","volume":"114","author":"\u00d6sterborg A.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27524"},{"key":"e_1_2_7_52_2","unstructured":"GlaxoSmithKline. \u201cInvestigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (RA) patients who had an inadequate response to TNF\u2010\u03b1 antagonist.\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT00603525. Accessed 22 March 2012."},{"key":"e_1_2_7_53_2","unstructured":"GlaxoSmithKline. \u201cInvestigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (RA) patients who had an inadequate response to methotrexate therapy.\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT00611455. Accessed 22 March 2012."},{"key":"e_1_2_7_54_2","unstructured":"GlaxoSmithKline. \u201cOfatumumab dose\u2010finding in relapsing remitting multiple sclerosis patients.\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT00640328. Accessed 22 March 2012."},{"key":"e_1_2_7_55_2","unstructured":"GlaxoSmithKline. \u201cA single\u2010arm international multi\u2010center trial investigating the efficacy and safety of ofatumumab retreatment and maintenance in CLL patients who progressed following response or stable disease after ofatumumab treatment in Hx\u2010CD20\u2010406.\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00802737?term=NCT00802737&rank=1. Accessed 22 March 2012."},{"key":"e_1_2_7_56_2","unstructured":"GlaxoSmithKline. \u201cA phase III open label randomized multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy (PROLONG).\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01039376?term=NCT01039376&rank=1. Accessed 5 April 2012."},{"key":"e_1_2_7_57_2","unstructured":"GlaxoSmithKline. \u201cAn open label multicenter study investigating the safety and efficacy of ofatumumab therapy versus physicians\u2019 choice in patients with bulky fludarabine\u2010refractory chronic lymphocytic leukaemia (CLL).\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01313689?term=NCT01313689&rank=1. Accessed 22 March 2012."},{"key":"e_1_2_7_58_2","unstructured":"GlaxoSmithKline. \u201cA phase II multi\u2010centre study investigating the safety and efficacy of ofatumumab and bendamustine combination in patients with untreated or relapsed chronic lymphocytic leukaemia (CLL).\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01520922?term=NCT01520922&rank=1. Accessed 22 March 2012."},{"key":"e_1_2_7_59_2","unstructured":"GlaxoSmithKline. \u201cA phase III open label randomized multicenter trial of ofatumumab added to chlorambucil versus chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia (COMPLEMENT 1).\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00748189?term=NCT00748189&rank=1. Accessed 22 March 2012."},{"key":"e_1_2_7_60_2","unstructured":"GlaxoSmithKline. \u201cA phase III open label randomized trial of ofatumumab added to fludarabine\u2010cyclophosphamide vs. fludarabine\u2010cyclophosphamide combination in subjects with relapsed chronic lymphocytic leukemia (COMPLEMENT 2).\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00824265?term=NCT00824265&rank=1. Accessed 22 March 2012."},{"key":"e_1_2_7_61_2","unstructured":"GlaxoSmithKline. \u201cPhase III randomized open label study of single agent ofatumumab versus single agent rituximab in follicular lymphoma relapsed after rituximab\u2010containing therapy (HOMER).\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01200589?term=NCT01200589&rank=1. Accessed 22 March 2012."},{"key":"e_1_2_7_62_2","unstructured":"GlaxoSmithKline. \u201cA randomized open label study of ofatumumab and bendamustine combination therapy compared with bendamustine monotherapy in indolent B\u2010cell non\u2010Hodgkin's lymphoma unresponsive to rituximab or a rituximab\u2010containing regimen during or within six months of treatment (COMPLEMENT A+B).\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01077518?term=NCT01077518&rank=1. Accessed 22 March 2012."},{"key":"e_1_2_7_63_2","unstructured":"GlaxoSmithKline. \u201cOfatumumab versus rituximab salvage chemoimmunotherapy followed by autologous stem cell transplant in relapsed or refractory diffuse large B cell lymphoma (ORCHARRD).\u201d Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01014208?term=NCT01014208&rank=1. Accessed 22 March 2012."}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2012.06661.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2012.06661.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:29:19Z","timestamp":1694939359000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2012.06661.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,25]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1749-6632.2012.06661.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06661.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,25]]}}}